ERBB2 and breast carcinoma: The anti-HER2 IgG trastuzumab (Herceptin) was selected as an appropriate antibody with which to undertake validation of the rebridging efficiency of the synthesised DVPs, on the basis of its successful use in the treatment of HER2-positive breast cancer, incorporation in multiple FDA-approved ADCs, and its widespread use in bioconjugation method development.